TSXV:RX - Post Discussion
Biosyent Inc
> BioSyent Long-term Extension of Cathejell® Agreement
Post by
Betteryear2 on Jun 20, 2023 8:00pm
BioSyent Long-term Extension of Cathejell® Agreement
MISSISSAUGA, Ontario, June 20, 2023 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its License, Distribution and Supply Agreement with its European partner for the Cathejell® product, extending BioSyent Pharma’s exclusive Canadian rights to Cathejell® until 2034. BioSyent Announces Long-term Extension of Cathejell® (globenewswire.com)
Be the first to comment on this post